The COVID-19 pandemic has illuminated an ongoing concern about antimicrobial resistance in dermatology and requires a recommitment from clinicians to follow guidelines that promote good stewardship.
Men with severe hair loss were significantly more likely to test positive for COVID-19, finds study data.
A first clinical experience with brodalumab in an HIV-positive patient proves successful and may imply the utility of brodalumab in this patient group.
According to Mylan, the administration of the recalled product may lead to “serious adverse events including, but not limited to, local irritation, vasculitis/phlebitis, antigenic or allergic reactions, and microvascular obstruction, including pulmonary embolism.”
SB206 12% represents a well-tolerated topical treatment for molluscum contagiosum that can be applied at home by patients or caregivers, solving an unmet medical need.
The association of S aureus with food sensitization and allergy could influence interventions aimed at inducing and maintaining tolerance to food allergens in eczematous infants.
Patients requiring systemic therapy for atopic dermatitis may benefit from lower infection risk treatments such as methotrexate, cyclosporine.
Seborrheic dermatitis is more prevalent in men and older people and has an increased rate of dermatological comorbidity.
The new recombinant zoster vaccine features a lower cost-effectiveness ratio than other recommended adult vaccines.
The patient, who presented to the clinical office complaining of dysuria, was diagnosed with a urinary tract infection and was prescribed TMP-SMX.
